Mecide Gharibo

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

Medicine, Oncology, Pharmacotherapy +14

<i>Lactobacillus rhamnosus GG</i> probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation

Elan Gorshein, Catherine Wei, Susan Ambrosy et al. · Clinical Transplantation · 2017 · 74 citations

Life Sciences, Immunology, Microbiology +17

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Cecilia Carpio, Réda Bouabdallah, Loïc Ysebaert et al. · Blood · 2020 · 73 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +8

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Sikander Ailawadhi, Kevin R. Kelly, Robert Vescio et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 64 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

Jamie Cavenagh, Heather Oakervee, P Baetiong-Caguioa et al. · British Journal of Cancer · 2017 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14